This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech Stock Mailbag: Orexigen Therapeutics

BOSTON (TheStreet) -- Not even another foot of snow (on top of the foot or so already on the ground) can keep the Biotech Stock Mailbag from making its appointed rounds.

HK Patel writes, "I have been following your articles since 2010 and I have learned a lot from them. My sincere thanks. Orexigen Therapeutics' (OREX) PDUFA date is Jan. 31 for their obesity drug. Adam, could you please comment on the prospects of its FDA approval or rejection?"

I was asked the same question on Twitter this week and my reply (prediction) was that Orexigen receives a complete response letter on Contrave, its obesity drug in waiting.

Now, that's a bit of dodge on my part because a large majority of investors believe Orexigen will receive a complete response letter. Orexigen and the U.S. Food and Drug Administration have had too little time since the Dec. 7 Contravy advisory panel meeting to resolve outstanding issues.

The real question is what flavor of complete response letter is coming? I see two varieties possible:

  • The "good" complete response letter is one in which FDA tells Orexigen that Contrave is approvable without the need for new pre-approval clinical studies or new efficacy and safety data. Full approval of Contrave would be granted later in 2011 after the two sides reach agreement on a post-approval trial to assess cardiovascular safety and nailing down a risk management plan.

    A "good" complete response letter pushes Orexigen's stock price higher.

  • The "bad" complete response letter is one in which FDA tells Orexigen that pre-approval clinical trials and/or efficacy and safety data are required before Contrave can be cleared for marketing.

    A "bad" complete response letter sends Orexigen's stock lower. How low depends on how much and what type of data FDA requires for approval. If the FDA goes against the wishes of the advisory panel and asks for a pre-approval cardiovascular outcomes study, Orexigen is cooked extra crispy. If the data request can be fulfilled without a new clinical trial and still leaves open the possibility of a 2011 Contrave approval, the stock may only fall a bit or even stay relatively flat.

Obviously, a full approval for Contrave on Jan. 31 is the best possible outcome for the drug and the stock.

My prediction: Drumroll….

Orexigen will receive a "good" complete response letter.

Feel free to ignore my guess since my obesity-stock prognostication track record hasn't been very sharp. The only thing I've been consistently right about is being bearish on Arena Pharmaceuticals (ARNA).

I polled 20 buysiders for their Contrave predictions: Ten (50%) expect a "bad" complete response letter; six (30%) believe a "good" complete response letter is coming; while a single respondent (5%) said he thought FDA would punt on making a decision altogether, meaning a delay in the approval decision date.

Another three buy-siders (15%) told me that they had no prediction at all. These folks may be the smartest of the group.

Stay tuned for the Contrave approval decision on Jan. 31.

One more Orexigen note: If FDA issues a complete response letter of any flavor, I personally challenge Orexigen management to publicly disclose the letter in full. Do not summarize the contents of the FDA's response in a press release or on a conference call.

Stock quotes in this article: OREX, VVUS, ARIA, CVM, AVNR, DSCO 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs